Estrogen receptor ligand treatment for neurodegenerative diseases
OwnerRhonda R Voskuhlinventor
Life of this patent
Estimating the term…
Abstract
The present invention relates to treatment of neurological diseases such as multiple sclerosis (MS) and Alzheimer's disease, using an estrogen receptor beta (ERβ) ligand in combination with a standard, anti-inflammatory agent.
Claims28
A method for treating the symptoms of a neurodegenerative disease in a mammal, the method comprising the steps of administering to the mammal a primary agent being an estrogen receptor ligand and a secondary agent being an immunotherapeutic compound.
The method of claim 7, wherein the estrogen receptor ligand is an estrogen receptor beta ligand.
A method to treat the symptoms of multiple sclerosis, comprising the steps of administering a primary agent estrogen receptor ligand and a secondary agent being an immunotherapeutic compound.
A compound agent for use in the treatment of the symptoms of a neurodegenerative disease, the compound comprising a primary agent being an estrogen receptor ligand and a secondary agent being an immunotherapeutic compound.
A compound agent for use in the treatment of the symptoms of a neurodegenerative disease, the compound comprising a primary agent being an estrogen receptor ligand and a secondary agent being an immunotherapeutic compound, whereby administration of the compound reduces demyelination in white matter.
A compound agent for use in the treatment of the symptoms of a neurodegenerative disease, the compound comprising a primary agent being an estrogen receptor ligand and a secondary agent being an immunotherapeutic compound, whereby administration of the compound reduces axonal loss in white matter.
A compound agent for use in the treatment of the symptoms of a neurodegenerative disease, the compound comprising a primary agent being an estrogen receptor ligand and a secondary agent being an immunotherapeutic compound, whereby administration of the compound reduces neuronal pathology in gray matter.
A compound agent for use in the treatment of the symptoms of a neurodegenerative disease, the compound comprising a primary agent being an estrogen receptor ligand and a secondary agent being an immunotherapeutic compound, whereby administration of the compound induces recovery of motor performance.
Use of at least one primary therapeutically active agent, the primary therapeutically active agent being an estrogen receptor ligand, in combination with a secondary active agent, the secondary active agent being beta interferon for the manufacture of a medicament for the therapeutic treatment of a neurodegenerative disease in a mammal.
Dependencies are inferred from the claim text.